晚期黑色素瘤的治疗进展综述
Progress in the Treatment of Advanced Melanoma
摘要: 黑色素瘤是世界上致命的癌症，晚期黑色素瘤恶性程度较高，由于发病比较隐匿，绝大多数病人诊断恶性黑色素瘤时疾病往往已经进入中晚期；黑色素瘤进入中晚期后治疗难度加大，手术切除及化疗的预后通常很差，随着对黑色素瘤不断深入地研究，在传统手术及化疗的基础上，出现了许多新的治疗方法，包括免疫治疗、靶向治疗及联合治疗等，本文对晚期黑色素瘤治疗的研究进展作一综述。
Abstract: Melanoma is a fatal cancer in the world. Advanced melanoma has a high degree of malignancy. Due to the hidden incidence, most patients often enter the middle and advanced stage when they diag-nose malignant melanoma; after melanoma enters the middle and advanced stage, the treatment becomes more difficult, and the prognosis of surgical resection and chemotherapy is usually very poor. With the continuous in-depth research on melanoma, many new treatment methods have emerged on the basis of traditional surgery and chemotherapy, including immunotherapy, targeted therapy and combined therapy. This paper summarizes the research progress of the treatment of advanced melanoma.
文章引用：谢艳琳, 马金华. 晚期黑色素瘤的治疗进展综述[J]. 临床医学进展, 2022, 12(6): 5256-5262. https://doi.org/10.12677/ACM.2022.126761

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. [Google Scholar] [CrossRef] [PubMed]
[2] Guo, J., Qin, S., Liang, J., et al. (2016) Chinese Guidelines on the Diagno-sis and Treatment of Melanoma (2015 Edition). Chinese Clinical Oncology, 5, 57. [Google Scholar] [CrossRef] [PubMed]
[3] Read, R.L., Haydu, L., Saw, R.P.M., et al. (2015) In-Transit Mela-noma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Annals of Surgical Oncology, 22, 475-481. [Google Scholar] [CrossRef] [PubMed]
[4] Dacarbazine—FDA Prescribing Information, Side Effects and Uses.
https://www.drugs.com/pro/dacarbazine.html
[5] Jiang, G., Li, R.H., Sun, C., et al. (2014) Dacarbazine Com-bined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis. PLoS One, 9, e111920. [Google Scholar] [CrossRef] [PubMed]
[6] Reid, J.M., Kuffel, M.J., Miller, J.K., et al. (1999) Metabolic Activation of Dacarbazine by Human Cytochromes P450: The Role of CYP1A1, CYP1A2, and CYP2E1. Clinical Can-cer Research, 5, 2192-2197.
https://go.drugbank.com/articles/A38929
[7] Middleton, M.R., Grob, J.J., Aaronson, N., et al. (2000) Random-ized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malig-nant Melanoma. Journal of Clinical Oncology, 18, 158-166. [Google Scholar] [CrossRef] 
[8] Guida, M., Tommasi, S., Strippoli, S., et al. (2018) The Search for a Melanoma-Tailored Chemotherapy in the New Era of Per-sonalized Therapy: A Phase II Study of Chemo-Modulating Temozolomide Followed by Fotemustine and a Cooperative Study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer, 18, Article No. 552. https://moh-it.pure.elsevier.com/en/publications/the-search-for-a-melanoma-tailored-chemotherapy-in-the-new-era-of [Google Scholar] [CrossRef] [PubMed]
[9] Quéreux, G. and Dréno, B. (2011) Fotemustine for the Treatment of Melanoma. Expert Opinion on Pharmacotherapy, 12, 2891-2904. [Google Scholar] [CrossRef] [PubMed]
[10] Legha, S., Ring, S., Papadopoulos, N., et al. (1990) A Phase II Trial of Taxol in Metastatic Melanoma. Cancer, 65, 2478-2481. [Google Scholar] [CrossRef] 
[11] Güven, K., Kittler, H., Wolff, K., et al. (2001) Cisplatin and Carboplatin Combination as Second-Line Chemotherapy in Dacarba-zine-Resistant Melanoma Patients. Melanoma Research, 11, 411-415. [Google Scholar] [CrossRef] [PubMed]
[12] 晚期黑色素瘤的免疫治疗进展——《医学综述》2019年24期[EB/OL].
https://www.cnki.com.cn/Article/CJFDTotal-YXZS201924009.htm, 2022-04-22.
[13] Hodi, F.S., O’Day, S.J., Mcdermott, D.F., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New Eng-land Journal of Medicine, 363, 711-723. [Google Scholar] [CrossRef] 
[14] Robert, C., Thomas, L., Bondarenko, I., et al. (2011) Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. The New England Journal of Medicine, 364, 2517-2526. [Google Scholar] [CrossRef] 
[15] Weber, J., Mandala, M., Del Vecchio, M., et al. (2017) Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. The New England Journal of Medicine, 377, 1824-1835. [Google Scholar] [CrossRef] 
[16] Eggermont, A.M.M., Blank, C.U., Mandala, M., et al. (2018) Adjuvant Pembrolizumab versus Placebo in Resected Stage III Mela-noma. The New England Journal of Medicine, 378, 1789-1801. [Google Scholar] [CrossRef] 
[17] Foundation, M.R. (2014) FDA Approves Pembrolizumab for Ad-vanced Melanoma.
https://www.prnewswire.com/news-releases/fda-approves-pembrolizumab-for-advanced-melanoma-274009831.html
[18] Herndon, T.M., Demko, S.G., Jiang, X., et al. (2012) U.S. Food and Drug Administration Approval: Peginter-feron-Alfa-2b for the Adjuvant Treatment of Patients with Melanoma. The Oncologist, 17, 1323-1328. [Google Scholar] [CrossRef] [PubMed]
[19] Eggermont, A,M,, Suciu, S., Santinami, M., et al. (2008) Adjuvant Therapy with Pegylated Interferon Alfa-2b versus Observation Alone in Resected Stage III Melanoma: Final Results of EORTC 18991, a Randomised Phase III Trial. Lancet (London, England), 372, 117-126. [Google Scholar] [CrossRef] 
[20] Sondak, V.K. and Kudchadkar, R. (2012) Pegylated Inter-feron for the Adjuvant Treatment of Melanoma: FDA Approved, But What Is Its Role. The Oncologist, 17, 1223-1224. https://europepmc.org/articles/PMC3481887 [Google Scholar] [CrossRef] [PubMed]
[21] Ott, P.A., Hu, Z., Keskin, D.B., et al. (2017) An Immuno-genic Personal Neoantigen Vaccine for Patients with Melanoma. Nature, 547, 217-221. [Google Scholar] [CrossRef] [PubMed]
[22] Khattak, M., Fisher, R., Turajlic, S., et al. (2013) Targeted Therapy and Immunotherapy in Advanced Melanoma: An Evolving Paradigm. Therapeutic Advances in Medical Oncology, 5, 105-118. [Google Scholar] [CrossRef] [PubMed]
[23] Chapman, P.B., Hauschild, A., Robert, C., et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. The New England Journal of Medicine, 364, 2507-2516. [Google Scholar] [CrossRef] 
[24] Phase III, Randomized, Open-Label, Multicenter Trial (BREAK-3) Comparing the BRAF Kinase Inhibitor Dabrafenib (GSK2118436) with Dacarbazine (DTIC) in Patients with BRAFV600E-Mutated Melanoma. Semantic Scholar.
https://www.semanticscholar.org/paper/Phase-III%2C-randomized%2C-open-label%2C-multicenter-the-Grob-Demidov/be6017e92512064e2199a08d8da97eca19d44726?msclkid=e2031aeac2b711ec80a5f150d8caac18
[25] Hauschild, A., Grob, J., Demidov, L., et al. (2013) An Update on BREAK-3, a Phase III, Randomized Trial: Dabrafenib (DAB) versus Dacarbazine (DTIC) in Patients with BRAF V600E-Positive Mutation Metastatic Melanoma (MM). Annals of Oncology, 25, iv374-iv393. [Google Scholar] [CrossRef] 
[26] Hoffner, B. and Benchich, K. (2018) Trametinib: A Targeted Therapy in Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology, 9, 741-745. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570520/ [Google Scholar] [CrossRef] 
[27] FDA (2019) FDA Approves Dabrafenib plus Trametinib for Adju-vant Treatment of Melanoma with BRAF V600E or V600K Mutations.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-adjuvant-treatment-melanoma-braf-v600e-or-v600k-mutations
[28] FDA Approves Cobimetinib Approved for Advanced Mel-anoma—National Cancer Institute.
https://www.cancer.gov/news-events/cancer-currents-blog/2015/cobimetinib-melanoma?msclkid=506475ebc2bc11ec8a4be0f0337d8287
[29] Combined BRAF and MEK Inhibition with PD-1 Blockade Immunotherapy in BRAF-Mutant Melanoma. Semantic Scholar.
https://www.semanticscholar.org/paper/Combined-BRAF-and-MEK-inhibition-with-PD-1-blockade-Ribas-Lawrence/feeb1335973f7d56963a3fdd3396c152a1ed8d4f?msclkid=579541b9c2bd11ec8d6bab60c011441e

为你推荐